Alnylam consolidates intellectual property for RNA activation
Alnylam Pharmaceuticals, Inc. has announced that it has consolidated the key intellectual property for RNA activation, creating a dominant IP position in this new area of biology.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.